Delphi Genetics Grants Merck License for the Use of the StabyExpress™ System

  Delphi Genetics Grants Merck License for the Use of the StabyExpress™ System

Business Wire

BRUSSELS -- October 08, 2012

Delphi Genetics SA (“Delphi”) has announced today a broad licensing agreement
with a subsidiary of Merck & Co., Inc., known as MSD outside the United States
and Canada, for the use of the StabyExpress™ technology, which allows high
yield, cost effective protein expression without the use of antibiotics.

Under the agreement, Merck receives a non-exclusive license to use the
StabyExpress™ technology for protein expression in research and product
development. In exchange, Delphi is eligible to receive milestone payments
associated with the development of Merck product candidates that utilize the
StabyExpress™ technology, as well as royalties on sales of such products. The
financial details of the agreement were not disclosed.

Cédric Szpirer PhD, Delphi Genetics Founder and CEO, explained: “This is
Delphi's first broad-based licensing agreement that covers potential use of
the StabyExpress™ technology for protein based product in the areas of human
and animal health.”

Guy Hélin, CBO, added: “This is the third licensing agreement that we have
announced with a world leading healthcare company. The non-exclusive nature of
this agreement enables us to consider similar collaborations with other
strategic partners, including partners in other fields than biopharma
production.”

Delphi also has licensing agreements with Sanofi-Pasteur, announced in June
2009, and with GSK, announced in September 2010.

About StabyExpress™

StabyExpress™ technology can be applied to any industrial protein production
process that involves bacterial fermentation. Biopharmaceutical production
represents a rapidly growing market and its share of the overall medication
market today is estimated at 15%. Moreover, the technology is consistent with
the recommendations of the FDA and the EMA with regard to the elimination of
Antibiotic Resistance Genes in protein production processes for both human and
veterinary uses. Currently, Antibiotic Resistance Genes are used as selection
markers for the design of the majority of the genetic systems enabling protein
production. The technology is also usable to produce DNA vaccines in order to
avoid completely the use of antibiotics resistance genes from DNA cloning to
DNA production.

About Delphi Genetics SA

Founded at the end of 2001, Delphi Genetics  develops more effective products
and technologies for genetic engineering and for protein expression in
bacteria by using its unique expertise in the field of plasmid stabilisation
systems. Delphi Genetics’ patented StabyExpress™ technology increases the
recombinant protein production output without the use of antibiotics, which is
the traditional approach. In January 2012, together with academic and Biotech
key-players, Delphi Genetics announced its participation in a research project
during the next 3 years for the development of DNA vaccines using the
technology. Other research projects are under way to adapt the technology to
mammalian cells and yeast.

For further information, please visit our website: www.delphigenetics.com

Rue Antoine de Saint Exupéry, 5
B-6041Gosselies, Belgium
+32 (0)71.25.10.00 (Tel)
+32 (0)71.37.60.57 (Fax)
www.delphigenetics.com

Contact:

Cédric Szpirer
Tel: +32 71 25 10 00
delphigenetics@delphigenetics.com
 
Press spacebar to pause and continue. Press esc to stop.